O	0	8	Informed
O	9	15	choice
O	16	21	about
O	22	28	breast
O	29	35	cancer
O	36	46	prevention
O	46	47	:
O	48	58	randomized
O	59	69	controlled
O	70	75	trial
O	76	78	of
O	79	81	an
O	82	88	online
O	89	97	decision
O	98	101	aid
O	102	114	intervention
O	114	115	.

O	116	125	Tamoxifen
O	126	129	and
O	130	140	raloxifene
O	141	144	are
O	145	160	chemopreventive
O	161	166	drugs
O	167	171	that
O	172	175	can
O	176	182	reduce
O	183	188	women
O	188	189	’
O	189	190	s
O	191	199	relative
O	200	204	risk
O	205	207	of
O	208	215	primary
O	216	222	breast
O	223	229	cancer
O	230	232	by
O	233	235	50
O	235	236	%
O	236	237	;
O	238	245	however
O	245	246	,
O	247	251	most
O	252	257	women
O	258	266	eligible
O	267	270	for
O	271	276	these
O	277	282	drugs
O	283	287	have
O	288	294	chosen
O	295	298	not
O	299	301	to
O	302	306	take
O	307	311	them
O	311	312	.

O	313	316	The
O	317	324	reasons
O	325	328	for
O	329	332	low
O	333	339	uptake
O	340	343	may
O	344	346	be
O	347	354	related
O	355	357	to
O	358	363	women
O	363	364	’
O	364	365	s
O	366	375	knowledge
O	376	378	or
O	379	388	attitudes
O	389	396	towards
O	397	400	the
O	401	406	drugs
O	406	407	.

O	408	410	We
O	411	416	aimed
O	417	419	to
O	420	427	examine
O	428	431	the
O	432	438	impact
O	439	441	of
O	442	444	an
B-intervention	445	451	online
I-intervention	452	458	breast
I-intervention	459	465	cancer
I-intervention	466	481	chemoprevention
I-intervention	482	490	decision
I-intervention	491	494	aid
I-intervention	495	496	(
I-intervention	496	498	DA
I-intervention	498	499	)
O	500	502	on
O	503	511	informed
O	512	522	intentions
O	523	526	and
O	527	536	decisions
O	537	539	of
B-eligibility	540	545	women
I-eligibility	546	548	at
I-eligibility	549	553	high
I-eligibility	554	558	risk
I-eligibility	559	561	of
I-eligibility	562	568	breast
I-eligibility	569	575	cancer
O	575	576	.

O	577	579	We
O	580	589	conducted
O	590	591	a
O	592	602	randomized
O	603	611	clinical
O	612	617	trial
O	617	618	,
O	619	628	assessing
O	629	632	the
O	633	639	effect
O	640	642	of
O	643	644	a
O	645	647	DA
O	648	653	about
O	654	660	breast
O	661	667	cancer
O	668	683	chemoprevention
O	684	686	on
O	687	695	informed
O	696	703	choices
O	704	709	about
O	710	725	chemoprevention
O	725	726	.

O	727	732	Women
O	733	734	(
O	734	735	n
O	736	737	=
B-total-participants	738	741	585
O	741	742	)
O	742	743	,
B-age	744	746	46
I-age	746	747	-
I-age	748	750	to
I-age	751	753	74
I-age	753	754	-
I-age	754	759	years
O	760	763	old
O	764	767	old
O	767	768	,
O	769	778	completed
O	779	785	online
O	786	794	baseline
O	794	795	,
O	796	800	post
O	800	801	-
O	801	805	test
O	805	806	,
O	807	810	and
O	811	816	three
O	816	817	-
O	817	822	month
O	823	829	follow
O	829	830	-
O	830	832	up
O	833	847	questionnaires
O	847	848	.

O	849	861	Participants
O	862	866	were
O	867	875	randomly
O	876	884	assigned
O	885	887	to
O	888	894	either
O	895	897	an
O	898	910	intervention
O	911	916	group
O	916	917	,
O	918	919	a
B-control	920	928	standard
I-control	929	936	control
I-control	937	942	group
O	943	947	that
O	948	956	answered
O	957	966	questions
O	967	972	about
O	973	988	chemoprevention
O	989	991	at
O	992	1000	baseline
O	1000	1001	,
O	1002	1004	or
O	1005	1006	a
B-control	1007	1012	three
I-control	1012	1013	-
I-control	1013	1018	month
I-control	1019	1026	control
I-control	1027	1032	group
O	1033	1037	that
O	1038	1041	did
O	1042	1045	not
O	1046	1052	answer
O	1053	1062	questions
O	1063	1068	about
O	1069	1084	chemoprevention
O	1085	1087	at
O	1088	1096	baseline
O	1096	1097	.

O	1098	1101	The
O	1102	1106	main
O	1107	1114	outcome
O	1115	1123	measures
O	1124	1128	were
B-outcome-Measure	1129	1136	whether
I-outcome-Measure	1137	1142	women
I-outcome-Measure	1142	1143	’
I-outcome-Measure	1143	1144	s
I-outcome-Measure	1145	1155	intentions
I-outcome-Measure	1156	1159	and
I-outcome-Measure	1160	1169	decisions
I-outcome-Measure	1170	1179	regarding
I-outcome-Measure	1180	1195	chemoprevention
I-outcome-Measure	1196	1201	drugs
I-outcome-Measure	1202	1206	were
I-outcome-Measure	1207	1215	informed
O	1215	1216	,
O	1217	1220	and
B-outcome-Measure	1221	1228	whether
I-outcome-Measure	1229	1234	women
I-outcome-Measure	1235	1238	who
I-outcome-Measure	1239	1245	viewed
I-outcome-Measure	1246	1249	the
I-outcome-Measure	1250	1252	DA
I-outcome-Measure	1253	1257	were
I-outcome-Measure	1258	1262	more
I-outcome-Measure	1263	1269	likely
I-outcome-Measure	1270	1272	to
I-outcome-Measure	1273	1277	make
I-outcome-Measure	1278	1286	informed
I-outcome-Measure	1287	1296	decisions
I-outcome-Measure	1297	1301	than
I-outcome-Measure	1302	1307	women
I-outcome-Measure	1308	1311	who
I-outcome-Measure	1312	1315	did
I-outcome-Measure	1316	1319	not
I-outcome-Measure	1320	1324	view
I-outcome-Measure	1325	1328	the
I-outcome-Measure	1329	1331	DA
O	1331	1332	,
O	1333	1338	using
O	1339	1340	a
O	1341	1352	dichotomous
O	1353	1362	composite
O	1363	1371	variable
O	1372	1373	‘
O	1373	1381	informed
O	1382	1388	choice
O	1388	1389	’
O	1390	1391	(
O	1391	1394	yes
O	1394	1395	/
O	1395	1397	no
O	1397	1398	)
O	1399	1401	to
O	1402	1410	classify
O	1411	1419	informed
O	1420	1429	decisions
O	1430	1432	as
O	1433	1438	those
O	1439	1449	reflecting
O	1450	1460	sufficient
O	1461	1470	knowledge
O	1471	1474	and
O	1475	1486	concordance
O	1487	1494	between
O	1495	1496	a
O	1497	1502	woman
O	1502	1503	’
O	1503	1504	s
O	1505	1513	decision
O	1514	1517	and
O	1518	1526	relevant
O	1527	1536	attitudes
O	1536	1537	.

O	1538	1546	Analyses
O	1547	1553	showed
O	1554	1558	that
O	1559	1563	more
O	1564	1576	intervention
O	1577	1581	than
O	1582	1590	standard
O	1591	1598	control
O	1599	1611	participants
O	1612	1613	(
B-iv-bin-percent	1613	1615	52
I-iv-bin-percent	1615	1616	.
I-iv-bin-percent	1616	1617	7
I-iv-bin-percent	1617	1618	%
O	1619	1625	versus
B-cv-bin-percent	1626	1627	5
I-cv-bin-percent	1627	1628	.
I-cv-bin-percent	1628	1629	9
I-cv-bin-percent	1629	1630	%
O	1630	1631	)
B-outcome	1632	1636	made
I-outcome	1637	1645	informed
I-outcome	1646	1655	decisions
O	1656	1658	at
O	1659	1663	post
O	1663	1664	-
O	1664	1668	test
O	1668	1669	,
O	1670	1671	P
O	1672	1673	<
O	1673	1674	0
O	1674	1675	.
O	1675	1678	001
O	1678	1679	.

O	1680	1682	At
O	1683	1686	the
O	1687	1692	three
O	1692	1693	-
O	1693	1698	month
O	1699	1705	follow
O	1705	1706	-
O	1706	1708	up
O	1708	1709	,
O	1710	1721	differences
O	1722	1724	in
B-outcome	1725	1730	rates
I-outcome	1731	1733	of
I-outcome	1734	1742	informed
I-outcome	1743	1749	choice
O	1750	1757	between
O	1758	1770	intervention
O	1771	1772	(
B-iv-bin-percent	1772	1774	16
I-iv-bin-percent	1774	1775	.
I-iv-bin-percent	1775	1776	9
I-iv-bin-percent	1776	1777	%
O	1777	1778	)
O	1779	1782	and
O	1783	1787	both
O	1788	1795	control
O	1796	1802	groups
O	1803	1804	(
B-cv-bin-percent	1804	1806	11
I-cv-bin-percent	1806	1807	.
I-cv-bin-percent	1807	1808	8
I-cv-bin-percent	1808	1809	%
O	1810	1813	and
B-cv-bin-percent	1814	1815	8
I-cv-bin-percent	1815	1816	.
I-cv-bin-percent	1816	1817	0
I-cv-bin-percent	1817	1818	%
O	1818	1819	)
O	1820	1824	were
O	1825	1838	statistically
O	1839	1842	non
O	1842	1843	-
O	1843	1854	significant
O	1854	1855	,
O	1856	1857	P
O	1858	1859	=
O	1860	1861	0
O	1861	1862	.
O	1862	1865	067
O	1865	1866	.

O	1867	1870	The
O	1871	1873	DA
O	1874	1883	increased
B-outcome	1884	1892	informed
I-outcome	1893	1901	decision
I-outcome	1902	1908	making
O	1909	1914	about
O	1915	1921	breast
O	1922	1928	cancer
O	1929	1944	chemoprevention
O	1944	1945	,
O	1946	1954	although
O	1955	1958	the
O	1959	1965	impact
O	1966	1968	on
O	1969	1978	knowledge
O	1979	1989	diminished
O	1990	1994	over
O	1995	1999	time
O	1999	2000	.

O	2001	2005	This
O	2006	2011	study
O	2012	2015	was
O	2016	2019	not
O	2020	2028	designed
O	2029	2031	to
O	2032	2041	determine
O	2042	2045	how
O	2046	2050	much
O	2051	2060	knowledge
O	2061	2069	decision
O	2070	2076	makers
O	2077	2081	must
O	2082	2088	retain
O	2089	2093	over
O	2094	2098	time
O	2098	2099	.

O	2100	2109	Examining
O	2110	2118	informed
O	2119	2128	decisions
O	2129	2138	increases
O	2139	2152	understanding
O	2153	2155	of
O	2156	2159	the
O	2160	2166	impact
O	2167	2169	of
O	2170	2173	DAs
O	2173	2174	.

O	2175	2176	A
O	2177	2185	standard
O	2186	2189	for
O	2190	2198	defining
O	2199	2202	and
O	2203	2212	measuring
O	2213	2223	sufficient
O	2224	2233	knowledge
O	2234	2237	for
O	2238	2246	informed
O	2247	2256	decisions
O	2257	2259	is
O	2260	2266	needed
O	2266	2267	.

O	2268	2282	ClinicalTrials
O	2282	2283	.
O	2283	2286	gov
O	2286	2287	:
O	2288	2299	NCT00967824
